Upstream & Downstream Processing

Collaboration looks to crystallization as alternative to multi-step chromatography

A European Union funded project to improve downstream processing is on track for completion by October 2020, says collaborator Fujifilm Diosynth Biotechnologies. The AMECRYS research project, funded through a €3.5 million ($4 million) grant through the European Union’s Horizon 2020 program, has brought together industry with government and academic institutes to develop alternatives to multi-step batch chromatography platforms. One of the collaborators is biologics contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies, which has reached a milestone in the…

GE to use Wego to make single-use products in China, for China

Wego Pharmaceutical Co. will manufacture single-use bioprocessing consumables on behalf of GE Healthcare from its facility in Weihai, China. The partnership with China’s Wego, financial details of which have not been divulged, will decrease product delivery times of GE Healthcare’s single-use bioprocessing products for Chinese biopharmaceutical companies, the firm says. “This collaboration helps local Chinese biomanufacturers focus on bringing much needed therapeutics to Chinese patients,” Olivier Loeillot, general manager of BioProcess at GE Healthcare Life Sciences, told BioProcess Insider. “Local…

Catalent pumping $200m into biomanufacturing expansions

Catalent plans to double fill/finish capacity at its Bloomington site and add a fourth and fifth train at its Madison drug substance facility. During its fourth quarter FY2018 call, contract development and manufacturing organization (CDMO) Catalent said it was eyeing up a fourth and fifth biomanufacturing train at its Madison, Wisconsin plant. And during its Q1 FY2019 investor call, CEO John Chiminski confirmed the board has approved both the expansion in Madison and a doubling of capacity at its Bloomington,…

Future market needs driving vendor innovation, says MilliporeSigma

MilliporeSigma has brought together its next-generation technologies, both acquired and developed in-house, under the formalized BioContiuum platform. The offering looks to obtain incremental process benefits now, with a mind to the continuous process of the future, the firm says. MilliporeSigma’s BioContinuum platform, its self-described holistic approach to next-generation bioprocessing, is being launched at the AAPS event in Washington DC next week. Ahead of the event, Andrew Bulpin, head of Process Solutions at the vendor, told BioProcess Insider how the offering…

High Octane: Lonza buys 80% of ‘game-changing’ cell therapy tech partner

Lonza has acquired a controlling stake in its partner Octane Biotech and will incorporate the closed and automated Cocoon processing tech into its autologous cell therapy offering. Contract development and manufacturing organization (CDMO) Lonza has collaborated with Octane Biotech for the past three years to develop the Cocoon manufacturing system. But this week, the Swiss CDMO purchased additional equity to hold a controlling stake of 80% in the firm, with an option for outright ownership. “Owning a controlling stake ensures…

Thermo Fisher services biz up 28% as Patheon enters the mix

Construction is underway at the ‘largest outsourced single-use site in North America’ says Thermo Fisher, a year after acquiring CDMO Patheon. In April 2018, Thermo Fisher Scientific announced a $50 million (€44 million) expansion at a plant in St Louis, Missouri to add 16,000 L of single-use capacity. The facility is run by contract development and manufacturing organization (CDMO) Patheon, acquired by Thermo Fisher in August 2017 for around $7.2 billion. And during a Q3 financial call, Thermo Fisher CEO…

Single-use, double-digits: Robust quarters for Pall and Sartorius

The “large molecule dynamic” underpins Pall Corporation’s continued quarterly double-digit growth, says owner Danaher. Fellow bioprocessing vendor Sartorius also saw double-digit gains in sales revenue and earnings. “Pall had a great quarter, producing double-digit core revenue growth,” Tom Joyce, CEO of Pall’s parent company Danaher Corporation told stakeholders during its recent third quarter financial call. “In particular, our biotech business, including single-use technologies was up mid-teens in the quarter.” For Danaher’s total business, Q3 sales were $4.85 billion (€4.25 billion),…

Aglaris talks automated and closed cell therapy platform

Anglo-Spanish firm Aglaris has developed an autonomous, closed production system for the manufacture of cell therapies such as T-cells and MSCs (Mesenchymal Stem Cells). According to new CEO Steven Docksey, the platform overcomes many issues associated with this new product class. “Most current processes are intensive, manual techniques derived and scaled-up from the cell preparation techniques used in research labs – adapting existing tools to the job. There is little in the way of genuine innovation that has come to…

Eli Lilly to demolish mothballed Erbitux plant in NJ

The former Imclone facility will be knocked down to give Eli Lilly “flexibility for future opportunities” at its Branchburg, New Jersey site, the firm says. Building 36 on Eli Lilly’s Branchburg, New Jersey campus is scheduled to be demolished by the end of the first quarter of 2019, Lilly spokesperson Tamara Ann Hull told BioProcess Insider. “A second building on the same campus – a new, higher capacity, modern facility, Building 50 – has been producing biologics since 2006. Therefore,…

Turning over a new Leaf? Plant-based expression as a disruptor

Plant-based protein expression offers high yields and easy harvesting but has been held back by a lack of funding and the ubiquity of mammalian and bacterial systems, says Leaf Expression Systems. UK-based contract biopharmaceutical development firm Leaf Expression Systems has appointed Simon Saxby, a former executive at contract manufacturing organizations (CMOs) Recipharm and Cobra, as its CEO. Leaf Expression Systems offers the production of proteins, antibodies and vaccines through its Hypertrans expression system, based on tobacco plants. Saxby’s immediate focus…